Shares of innovative drug companies are leading gains in the Hong Kong market.

SKB BIO (06990) rose 10.5% to HK$550.5, while INNOVENT BIO (01801) gained 8.38% to HK$97.6. AKESO (09926) advanced 7.88% to HK$103.4, and 3SBIO (01530) increased by 7.71% to HK$18.73.

The catalyst for the move is the recent joint release of the National Essential Medicines List (2026 Edition) by three national agencies, including the National Health Commission. This new edition, effective from September 1, 2026, represents the first major systematic update to the list in eight years since the 2018 version.

This update is widely viewed by the market as a landmark shift in the policy environment for the innovative drug sector. According to a leading healthcare industry analyst, the most significant highlight of this adjustment is the first-time inclusion of domestically developed Class I innovative drugs, GLP-1 therapies, monoclonal antibodies, and targeted anti-cancer drugs. This breaks the previous convention of the Essential Medicines List excluding high-cost innovative treatments.

The move sends a strong policy signal of support for innovative drug development. It significantly broadens the pathway for these drugs to enter grassroots healthcare settings and the essential medicines system, providing clear policy backing and expanded market potential for the high-quality development of China's domestic innovative pharmaceutical industry.

With deeper coordination and linkage expected between the Essential Medicines List and the national medical insurance system, the grassroots adoption of innovative drugs is poised to accelerate substantially.